MUMBAI, February 24, 2015 /PRNewswire/ --
Two manufacturing facilities of Glenmark located in Goa and Nashik bagged the prestigious 'Greentech Environment Gold Award - 2015' for Excellence in Environment Management at a ceremony in Kolkata recently. Greentech Environment Awards are presented ever year to companies/units in India demonstrating the highest level of commitment to Environmental Management across different sectors.
"The coveted Gold Accolade from Greentech Foundation is a testament of our commitment towards Environment Protection. We are dedicated to conducting our business responsibly in the area of Environment, Health and Safety across all our operations. At our Goa and Nashik plants we have taken a number of steps in conserving natural resources, preventing pollution and minimizing environmental impact which has resulted into this award," said Cheryl Pinto, Director Corporate Affairs - Glenmark.
Greentech Foundation, established in the year 2000 and based at New Delhi, is a non-profit organization committed to recognize and celebrate ethos of outstanding performance in Environment Protection, Fire & Safety, HR and CSR. Greentech Foundation Awards honors the proactive practices of awardees enhancing their esteem.
Glenmark's manufacturing facility in Goa manufactures oral solids, semi solids and hormones. It is approved by regulatory bodies like US FDA, TPD (Canada), MCC (South Africa), WHO-GMP, ANVISA (Brazil) and MHRA (UK).
The Nasik facility which began operations in the year 1983 is Glenmark's first manufacturing facility. Today the facility manufactures more than 200 products catering to the bulk of the demand for solid orals, liquid orals, and external creams and powders in over 70 markets in Asia [including India], Africa, CIS/Russia and Latin America.
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014).
Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].
For further information please visit: http://www.glenmarkpharma.com
SOURCE Glenmark Pharmaceuticals